



11W 2821

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Reply, Refer to the Application of: Qiwang Xu et al.

Serial No.: 10/551,081

Filed: March 29, 2007

Title: USE OF N-ACETYL-D-GLUCOSAMINE  
IN TREATMENT OF LOCAL LESIONS  
OR SYSTEMATIC SYMPTOMS  
RELATED TO AUTOIMMUNE  
REACTIONS

Seyfarth Shaw Matter: 33888-400200

Date: August 28, 2007

)  
) Group Art Unit: 2821  
)  
) Confirmation No. 1679  
)  
) **Customer No. 27717**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants' assignee's undersigned attorneys, are aware of the references listed on the attached Form PTO/SB/08A and 8B, copies of which are enclosed, and which are relevant to said application.

It is believed that no fee is required. However, if there is a fee, you are authorized to charge same to Deposit Account No. 19-1351.

Respectfully submitted,

Seyfarth Shaw LLP  
Attorneys for Assignee  
131 S. Dearborn Street - Suite 2400  
Chicago, Illinois 60603-5577  
312-460-5000

By:   
Harold V. Stotland (Reg. No. 24,492)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/551,081
Filing Date	March 29, 2007
First Named Inventor	Qiwang Xu
Group Art Unit	2821
Examiner Name	
Attorney Docket Number	33888-400200

Sheet	1	of	3
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>8</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		WO	03/002117	A2	Astion Development	01/09/2003		
		WO	03/002117	A3	Astion Development	01/09/2003		
		WO	03/002125	A2	Astion A/S	09/09/2003		
		EP	0379753	A1	Ulrich Speck	08/01/1990		
		DE	3927723	A1	Ulrich Speck	08/02/1990		
		WO	9008549	A1	Ulrich Speck	08-09-1990		
		DE	58902712	D1	Ulrich Speck	12-17-1992		
		ES	2052893	T3	Ulrich Speck	07-16-1994		
		GR	3006815	T3	Ulrich Speck	06-30-1993		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+

+

+

+

+

**Complete if Known**

Application Number	10/551,081
Filing Date	March 29, 2007
First Named Inventor	Qiwang Xu
Group Art Unit	2821
Examiner Name	
Attorney Docket Number	33888-400200

Application Number	10/551,081
Filing Date	March 29, 2007
First Named Inventor	Qiwang Xu
Group Art Unit	2821
Examiner Name	
Attorney Docket Number	33888-400200

Application Number	10/551,081
Filing Date	March 29, 2007
First Named Inventor	Qiwang Xu
Group Art Unit	2821
Examiner Name	
Attorney Docket Number	33888-400200

[illegible][illegible]

Date Considered

Date Considered

Date Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/551,081
		Filing Date	March 29, 2007
		First Named Inventor	Qiwang Xu
		Art Unit	2821
		Examiner Name	
Sheet 3 of 3	Attorney Docket Number	33888-400200	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Manna R., et al. "psoriasis: an autoimmune disease" Minerva Medica, 1992, Italy, vol. 83, no. 7-8, 1992, pages 403-414	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.